Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study

A Bettiol, ML Urban, L Dagna, V Cottin… - Arthritis & …, 2022 - Wiley Online Library
Objective Mepolizumab proved to be an efficacious treatment for eosinophilic
granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the …
被引用次数：98 相关文章

Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study

A Bettiol, ML Urban, L Dagna, V Cottin… - ARTHRITIS & …, 2021 - research.unipd.it
Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA,
former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA …
[PDF] wiley.com

[PDF][PDF] Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

A Bettiol, ML Urban, L Dagna, V Cottin… - Arthritis & …, 2022 - Wiley Online Library
Objective Mepolizumab proved to be an efficacious treatment for eosinophilic
granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the …

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.

A Bettiol, ML Urban, L Dagna, V Cottin… - Arthritis & …, 2021 - europepmc.org
Objective Mepolizumab proved to be an efficacious treatment for eosinophilic
granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the …

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

A Bettiol, ML Urban, L Dagna… - Arthritis & …, 2022 - cris.maastrichtuniversity.nl
Objective Mepolizumab proved to be an efficacious treatment for eosinophilic
granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the …

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

A Bettiol, ML Urban, L Dagna, V Cottin… - ARTHRITIS & …, 2021 - air.uniud.it
Objective: Mepolizumab proved to be an efficacious treatment for eosinophilic
granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the …

Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study

A Bettiol, ML Urban, L Dagna, V Cottin… - ARTHRITIS & …, 2021 - iris.unimore.it
Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA,
former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA …

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

A Bettiol, ML Urban, L Dagna, V Cottin… - ARTHRITIS & …, 2022 - arpi.unipi.it
Objective: Mepolizumab proved to be an efficacious treatment for eosinophilic
granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the …

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

A Bettiol, ML Urban, L Dagna, V Cottin… - ARTHRITIS & …, 2022 - iris.univr.it
Objective: Mepolizumab proved to be an efficacious treatment for eosinophilic
granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the …

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

A Bettiol, AJ Mohammad, E Yacyshyn… - Arthritis and …, 2022 - portal.research.lu.se
Objective Mepolizumab proved to be an efficacious treatment for eosinophilic
granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the …